Patent · US Active

Salts, co-crystals, and polymorphs of an anxiolytic compound

US9745296B2 · kind B2 · utility

0Cited by

0References

15Claims

0Family size

Assignees

Bionomics Limited · AU
IRONWOOD PHARMACEUTICALS, INC. · US

Inventors

Bernard Luke Flynn · Melbourne, AU
Dharam Paul · Yarrawonga, AU
Andrew John Harvey · Adelaide, AU
Vasu Sethuraman · Waltham, US
Raymond E. Forslund · Natick, US
Song Xue · Newton, US
Rob Livingston · Cambridge, US
Ahmad Hashash · Cambridge, US

Key dates

Filing date	Mar 14, 2014
Grant date	Aug 29, 2017
Priority date	—
Expiry date	Mar 14, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C55/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides amorphous arid crystalline forms of 1-ethyl-6-(indan-2-ylamino)-3-(morpholine-4-carbonyl)-1,8-naphthyridin-4-one (compound 1), and salts, co-crystals, and pharmaceutical compositions thereof. The invention also provides methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using the amorphous and crystalline forms, and salts, co-crystals, and pharmaceutical compositions thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.